{"id":2248,"date":"2024-03-16T13:21:00","date_gmt":"2024-03-16T13:21:00","guid":{"rendered":"https:\/\/physiciansurveypanel.com\/?p=2248"},"modified":"2026-02-26T13:25:54","modified_gmt":"2026-02-26T13:25:54","slug":"the-bio-convergence-why-2024-is-the-year-of-3d-bioprinting-and-organ-chips","status":"publish","type":"post","link":"https:\/\/physiciansurveypanel.com\/index.php\/2024\/03\/16\/the-bio-convergence-why-2024-is-the-year-of-3d-bioprinting-and-organ-chips\/","title":{"rendered":"The Bio-Convergence: Why 2024 is the Year of 3D Bioprinting and Organ-Chips"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\n\t\n<\/svg>\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Reading time: 06 minutes<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Team PSP | 16\/03\/2024<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The medical landscape of 2024 is no longer defined by “one-size-fits-all” treatments. We\u2019ve entered a decade where the line between biology and engineering has effectively vanished.<\/p>\n

At the heart of this revolution are two synergistic powerhouses: 3D Bioprinting<\/strong> and Organ-on-a-Chip (OoC)<\/strong>.<\/p>\n

While the previous few years focused on the potential<\/em> of these technologies, 2024 is seeing them move into clinical reality. From the FDA\u2019s groundbreaking inclusion of non-animal data in drug approvals to the successful implantation of complex bioprinted scaffolds, we are witnessing the birth of truly personalized medicine.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"16Mar24\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

3D Bioprinting: From Digital Blueprints to Living Tissue<\/strong><\/h4>\n

3D Bioprinting is the precise, layer-by-layer deposition of “bio-inks”\u2014a cocktail of living cells, hydrogels, and growth factors\u2014guided by high-resolution medical imaging like MRI or CT scans.<\/p>\n

What\u2019s New in 2024?<\/strong><\/h4>\n
    \n
  • Vascularization Breakthroughs:<\/strong> The biggest hurdle\u2014keeping bioprinted tissues “alive” via blood flow\u2014is being solved. New techniques in volumetric bioprinting<\/strong> and sacrificial inks<\/strong> allow us to print intricate networks of capillaries inside larger structures.<\/li>\n
  • Smart Bio-inks:<\/strong> We are now using “dynamic covalent hydrogels” that can change shape and respond to cellular forces, mimicking the real-life behavior of the human body\u2019s extracellular matrix.<\/li>\n
  • Point-of-Care Printing:<\/strong> Some hospitals are now equipped with on-site bioprinters to create custom skin grafts for burn victims or bone scaffolds for complex orthopedic surgeries right in the operating theater.<\/li>\n<\/ul>\n

    \u00a0<\/strong>The 2024 Bioprinting Power Players<\/strong><\/h4>\n\n\n\n\n\n\n\n\n\n
    \n

    Company<\/strong><\/p>\n<\/td>\n

    		\n

    Specialty<\/strong><\/p>\n<\/td>\n

    		\n

    Recent Milestone<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/thead>\n

    \n

    Organovo<\/strong><\/p>\n<\/td>\n

    		\n

    Clinical Tissues<\/p>\n<\/td>\n

    		\n

    Focused on 3D-printed liver and kidney tissues for disease modeling and therapeutic repair.<\/p>\n<\/td>\n<\/tr>\n

    \n

    Cellink<\/strong><\/p>\n<\/td>\n

    		\n

    Bioprinting Ecosystem<\/p>\n<\/td>\n

    		\n

    Their newest systems integrate AI<\/strong> to predict cell viability during the printing process.<\/p>\n<\/td>\n<\/tr>\n

    \n

    Aspect Biosystems<\/strong><\/p>\n<\/td>\n

    		\n

    Tissue Therapeutics<\/p>\n<\/td>\n

    		\n

    Developing bioprinted “bio-replacement” therapies to treat metabolic diseases like Type 1 Diabetes.<\/p>\n<\/td>\n<\/tr>\n

    \n

    Cyfuse Biomedical<\/strong><\/p>\n<\/td>\n

    		\n

    Scaffold-Free Printing<\/p>\n<\/td>\n

    		\n

    Using their “Kenzan” method to create dense, 100% cellular tissue without synthetic supports.<\/p>\n<\/td>\n<\/tr>\n

    \n

    TeVido Biodevices<\/strong><\/p>\n<\/td>\n

    		\n

    Specialized Reconstruction<\/p>\n<\/td>\n

    		\n

    Leading the way in nipple and areola reconstruction for breast cancer survivors using a patient’s own cells.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    \u00a0<\/strong>Organ-on-a-Chip: The Death of Animal Testing?<\/strong><\/h4>\n

    An Organ-on-a-Chip<\/strong> is a microfluidic device that mimics the physical and chemical environment of a human organ. It\u2019s not just a petri dish; it\u2019s a living, breathing (literally, in the case of Lung-on-a-Chip) model of human physiology.<\/p>\n

    The 2024 Regulatory Shift<\/strong><\/h4>\n

    The FDA\u2019s ISTAND Pilot Program<\/strong> reached a historic milestone in late 2023 and early 2024 by officially accepting the first Organ-Chip data to predict drug-induced liver injury. This signals a massive move away from traditional animal models, which often fail to predict human reactions.<\/p>\n

      \n
    • Multi-Organ Systems:<\/strong> We are now seeing “Body-on-a-Chip” setups where a “gut” chip is linked to a “liver” chip, allowing researchers to see how a drug is absorbed and then metabolized in real-time.<\/li>\n
    • Personalized “Avatars”:<\/strong> By using a patient’s own stem cells (iPSCs<\/strong>), doctors can now test a drug on a “Liver-on-a-Chip” of that specific patient<\/em> before prescribing it, ensuring zero side effects.<\/li>\n<\/ul>\n

      The Leaders in Micro-Physiological Systems<\/strong><\/h4>\n
        \n
      • Emulate Inc:<\/strong> Their Human-on-a-Chip<\/strong> platform is the industry standard, recently used to study the long-term effects of radiation and viral infections like COVID-19.<\/li>\n
      • AxoSim Inc:<\/strong> Revolutionizing neuroscience by using their “Nerve-on-a-Chip” to find cures for ALS and Alzheimer\u2019s.<\/li>\n
      • Hesperos:<\/strong> Specialists in “pumpless” microfluidic systems that can sustain multiple organs for weeks of drug testing.<\/li>\n
      • Altis Biosystems:<\/strong> Their “RepliGut” system is the most accurate model of the human intestinal tract available today.<\/li>\n<\/ul>\n

        Conclusion: A Scaffold for the Future<\/strong><\/h4>\n

        The convergence of bioprinting and OoC is creating a world where we no longer wait for a donor; we print the solution. In 2024, the focus has shifted from “Can we build a tissue?” to “How fast can we get this to the patient?” With the FDA now backing these digital-biological hybrids, the future of artificial organs isn’t just a science fiction dream\u2014it\u2019s the new standard of care.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

        \n\t\t\t\t\t

        Share<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
        \n\t\t\t\t
        \n\t\t\t\t\t
        \t\t
          \n
        • \n
          \n \n <\/i> \n <\/div>\n <\/li>\n
        • \n
          \n \n <\/i> \n <\/div>\n <\/li>\n <\/ul>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
          \n\t\t\t\t\t
          \n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

          The medical landscape of 2024 is no longer defined by “one-size-fits-all” treatments. We\u2019ve entered a decade where the line between biology and engineering has effectively vanished.<\/p>\n

          At the heart of this revolution are two synergistic powerhouses: 3D Bioprinting and Organ-on-a-Chip (OoC).<\/p>\n","protected":false},"author":2,"featured_media":2249,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs"],"_links":{"self":[{"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/posts\/2248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/comments?post=2248"}],"version-history":[{"count":4,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/posts\/2248\/revisions"}],"predecessor-version":[{"id":2253,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/posts\/2248\/revisions\/2253"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/media\/2249"}],"wp:attachment":[{"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/media?parent=2248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/categories?post=2248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/tags?post=2248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}